NEW YORK, Aug. 15, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) announced that the Company recently hosted a symposium at the Interventional Radiology and Endovascular Surgery Society Meeting (SOBRICE) in Buzios, Brazil. The session, titled "Chemosaturation PHP – A New Evidenced-Based Technology for the Treatment of Liver Tumors," was held on Wednesday, August 10, 2011, and featured a presentation by Delcath's Executive Vice President of Research and Development and Chief Medical Officer, Krishna Kandarpa, MD, PhD.
Moderated by conference chairman Dr. Ricardo Pinto, the symposium also featured presentations from clinical leaders in interventional oncology. Dr. Riccardo Lencioni, Associate Professor of Radiology and Head of Diagnostic Imaging and Intervention in the Department of Liver Transplantation, Hepatology and Infectious Diseases of the University of Pisa, led a discussion titled, "Evolution of Liver Directed Cancer Therapies." In addition, Dr. Nestor Kisilevzky, a past President of the Brazilian Society of Interventional Radiology and a key interventional radiology opinion leader in Brazil and Latin America, presented, "Potential Applications of Chemosaturation PHP in Brazil and Latin America." The symposium was well attended and generated a robust discussion among the over 120 participating clinicians.
"SOBRICE was attended by a broad audience of clinical experts from Latin America and around the world, and offered an excellent forum for discussing promising therapies like our chemosaturation system," said Mr. Kandarpa. "We believe the strong attendance at our symposium reflects the potential that the global clinical community sees in chemosaturation for the treatment of unresectable cancer tumors in the liver."
About Delcath SystemsDelcath Systems, Inc. is a development stage specialty p
|SOURCE Delcath Systems, Inc.|
Copyright©2010 PR Newswire.
All rights reserved